REPUBLIKA.CO.ID, SINGAPORE -- In Japan and the United States (US), the use of immunotherapy is approved to treat patients with melanoma (skin cancer). The researchers found that after one year, overall survival rate in patients who received immunotherapy for advanced stage of melanoma is 94 percent.

Meanwhile, the survival rate for two years reached 88 percent. The US Agency for Food and Drug Administration (FDA) approved the certification of immunotherapy to treat people which is affected by lung cancer advanced stage. Clinical trials that were conducted on lung cancer showed promising results, which could improve patient survival from 8.2 months to 9.2 months.

Immunotherapy is a relatively new form of anti-cancer treatment that has given promising results in the past years. Although promising, the new treatment methods do not stop human struggle against cancer.

"It is important that the patient knows, like all medical treatments, there are certain limitations that can be achieved by immunotherapy," said Medical Director and Senior Consultant of Medical Oncology at Parkway Cancer Center, Dr Ang Peng Tiam, in a press release received by Republika.co.id.

To that end, people have duty and responsibility to share and remove misunderstandings about the immunotherapy.

Ikuti Whatsapp Channel Republika